PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. Biomed. Res. Ther. [Internet]. 2023 Dec. 31 [cited 2024 Nov. 15];10(12):6090-102. Available from: https://preservation.bmrat.org/index.php/BMRAT/article/view/851